Abstract
Among 214 patients treated with abciximab within 24 hours of full-dose thrombolytic therapy, major bleeding occurred in 50 patients (23%; 95% confidence interval [CI] 18% to 30%) and intracranial hemorrhage occurred in 3 patients (1.4%; 95% CI 0.3% to 4%). The independent multivariate predictors of major bleeding were age (odds ratio [OR] 1.53/10 years, 95% CI 1.05 to 2.21, p = 0.03), time from thrombolytic to abciximab (OR 0.91/hour, 95% CI 0.83 to 0.99, p = 0.03), and intra-aortic balloon pump insertion (OR 4.42, 95% CI 2.00 to 9.72, p = 0.0002).
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Abciximab
-
Aged
-
Angioplasty
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal / therapeutic use
-
Female
-
Fibrinolytic Agents / therapeutic use
-
Hemorrhage / chemically induced*
-
Humans
-
Immunoglobulin Fab Fragments / adverse effects*
-
Immunoglobulin Fab Fragments / therapeutic use
-
Logistic Models
-
Male
-
Middle Aged
-
Myocardial Infarction / complications
-
Myocardial Infarction / surgery
-
Myocardial Ischemia / etiology
-
Myocardial Ischemia / prevention & control
-
Platelet Aggregation Inhibitors / adverse effects*
-
Platelet Aggregation Inhibitors / therapeutic use
-
Recombinant Proteins / therapeutic use
-
Risk Factors
-
Thrombolytic Therapy
-
Tissue Plasminogen Activator / therapeutic use
-
Treatment Failure
Substances
-
Antibodies, Monoclonal
-
Fibrinolytic Agents
-
Immunoglobulin Fab Fragments
-
Platelet Aggregation Inhibitors
-
Recombinant Proteins
-
reteplase
-
Tissue Plasminogen Activator
-
Abciximab